Etrumadenant is a dual A2A AR/A2B AR antagonist currently in clinical trials for cancer [228,229] but is reported here as an example of a dual-targeting ligand that, due to the complex regulation in the CNS by different AR subtypes, could be an effective strategy for the treatment of neurodegenerative diseases. This evidence concerns the gene AR and neurodegenerative disease.